Cape ANN Savings Bank Cuts Stake in Pfizer Inc. (NYSE:PFE)

Cape ANN Savings Bank lowered its position in shares of Pfizer Inc. (NYSE:PFEGet Rating) by 9.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,258 shares of the biopharmaceutical company’s stock after selling 1,859 shares during the period. Cape ANN Savings Bank’s holdings in Pfizer were worth $893,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in PFE. SC&H Financial Advisors Inc. purchased a new position in Pfizer in the fourth quarter valued at about $251,000. Candriam Luxembourg S.C.A. grew its stake in Pfizer by 230.8% in the fourth quarter. Candriam Luxembourg S.C.A. now owns 443,077 shares of the biopharmaceutical company’s stock valued at $26,164,000 after purchasing an additional 309,129 shares during the last quarter. Cumberland Partners Ltd purchased a new position in Pfizer in the fourth quarter valued at about $588,000. Csenge Advisory Group grew its stake in shares of Pfizer by 14.9% during the fourth quarter. Csenge Advisory Group now owns 49,633 shares of the biopharmaceutical company’s stock worth $1,963,000 after acquiring an additional 6,450 shares during the last quarter. Finally, Paragon Capital Management LLC purchased a new stake in shares of Pfizer during the fourth quarter worth about $237,000. Hedge funds and other institutional investors own 67.90% of the company’s stock.

Pfizer Trading Down 3.3 %

Shares of PFE stock opened at $46.19 on Wednesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.42 and a quick ratio of 1.20. The company has a market cap of $259.23 billion, a price-to-earnings ratio of 9.04, a PEG ratio of 0.59 and a beta of 0.70. The stock has a 50 day simple moving average of $49.41 and a 200-day simple moving average of $50.46. Pfizer Inc. has a 1-year low of $40.94 and a 1-year high of $61.71.

Pfizer (NYSE:PFEGet Rating) last announced its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.95 by $0.09. The business had revenue of $27.74 billion during the quarter, compared to the consensus estimate of $26.20 billion. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. The business’s quarterly revenue was up 46.8% on a year-over-year basis. During the same period in the prior year, the company posted $1.07 EPS. On average, equities research analysts expect that Pfizer Inc. will post 6.54 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Wednesday, June 29th were given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 3.46%. The ex-dividend date of this dividend was Thursday, July 28th. Pfizer’s payout ratio is 31.31%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. set a $57.00 price target on Pfizer in a research note on Tuesday, June 28th. Barclays set a $50.00 price target on Pfizer in a research note on Thursday, September 1st. UBS Group set a $59.00 target price on Pfizer in a report on Thursday, September 1st. The Goldman Sachs Group set a $50.00 target price on Pfizer in a report on Thursday, September 1st. Finally, Morgan Stanley decreased their target price on Pfizer from $52.00 to $49.00 and set an “equal weight” rating for the company in a report on Friday, July 8th. Nine research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from, the stock presently has an average rating of “Moderate Buy” and an average target price of $57.33.

Pfizer Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

See Also

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.